Central nervous system involvement in AIDS-related lymphomas

Area of Science:

• Oncology
• Infectious Diseases
• Neurology

Background:

• Central nervous system (CNS) involvement is a frequent complication of acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL).
• Understanding factors influencing CNS involvement at diagnosis and relapse is crucial for patient outcomes.
• The impact of combination antiretroviral therapy (cART) on CNS involvement in ARL requires further elucidation.

Purpose of the Study:

• To identify factors associated with CNS involvement at baseline (CNS(B)) and relapse (CNS(R)) in patients with newly diagnosed ARL.
• To evaluate the outcomes, including overall survival (OS), for patients experiencing CNS(B) and CNS(R).
• To assess the effectiveness of intrathecal (IT) prophylaxis in preventing CNS relapse.

Main Methods:

• Retrospective analysis of 886 patients with newly diagnosed ARL.
• Evaluation of CNS involvement at baseline (CNS(B)) and during follow-up for relapse (CNS(R)).
• Multivariate analysis to determine factors associated with CNS(R), including CNS(B) and response to initial therapy.

Main Results:

• CNS involvement at baseline (CNS(B)) was observed in 13% of patients and did not impact overall survival (OS).
• 5.3% of patients experienced CNS relapse (CNS(R)), with a median OS of 1.6 months post-relapse.
• CNS(B) (HR 3.68) and complete response to initial therapy (HR 0.14) were significantly associated with CNS(R).

Conclusions:

• CNS involvement in ARL occurs early and is associated with poor outcomes upon relapse.
• Complete response to initial therapy is a key factor in reducing the frequency of CNS relapse.
• While CNS(B) increases the risk of CNS relapse, it does not negatively affect overall survival in ARL patients.